Tarceva 150 mg film-coated tablets

DRUG2 trials

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Region Hovedstaden

Conditions

Advanced solid tumorMetastatic non-clear cell renal cell carcinomaMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemia

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma

Active, not recruitingCTIS2024-519070-39-00

Region HovedstadenMetastatic non-clear cell renal cell carcinoma

Start: 2020-03-06Target: 30Updated: 2024-10-31

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01